US Executive Compensation Proxy SEC Filings β June 30, 2026
The 9 filings in this stream reveal a mix of routine governance proposals and a few significant corporate actions. Notable trends include two Nuveen municipal bond funds proposing mergers to streamline operations, which carry tax implications for shareholders. Silo Pharma seeks a massive increase in authorized shares (from 6.7M to 250M), a potential dilution risk. Insider trading activity is absent across filings, limiting conviction signals. Compensation data shows mixed trends: Silo Pharma's PEO pay declined 21% YoY while average non-PEO NEO pay rose 8%. Most filings are low-materiality proxy statements with standard director elections and auditor ratifications. The upcoming annual meetings in July-August 2026 create a catalyst calendar for governance votes.